These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 17174843)

  • 1. Off-label uses of biologic agents in dermatology: a 2006 update.
    Kerns MJ; Graves JE; Smith DI; Heffernan MP
    Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).
    Smith DI; Swamy PM; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Biologic Therapies in Dermatology.
    Fathi R; Armstrong AW
    Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative uses of rituximab in dermatology.
    Carr DR; Heffernan MP
    Dermatol Clin; 2010 Jul; 28(3):547-57. PubMed ID: 20510764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label use in dermatology in Germany: what has changed since 2004.
    Brockmeyer NH; Brucklacher U; Potthoff A; Reich-Schupke S
    J Dtsch Dermatol Ges; 2009 Nov; 7(11):938-45. PubMed ID: 19386019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic drugs--safe, effective, and affordable.
    Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
    Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology.
    Bellodi-Schmidt F; Shah KN
    Pediatr Dermatol; 2016; 33(1):18-27. PubMed ID: 26607958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of biologicals in the management of inflammatory oral mucosal disease.
    O'Neill ID
    J Oral Pathol Med; 2008 Nov; 37(10):575-81. PubMed ID: 18764859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label dermatologic therapies. Usage, risks, and mechanisms.
    Li VW; Jaffe MP; Li WW; Haynes HA
    Arch Dermatol; 1998 Nov; 134(11):1449-54. PubMed ID: 9828883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of systemic immune moderators in dermatology: an update.
    Kazlow Stern D; Tripp JM; Ho VC; Lebwohl M
    Dermatol Clin; 2005 Apr; 23(2):259-300. PubMed ID: 15837155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sources of drug information: FDA-approved labeling and other official FDA sources.
    Lindstrom JA
    Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
    Sockolov ME; Alikhan A; Zargari O
    J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs and other product choices.
    Hyman PM; Carvajal R
    Dermatol Ther; 2009; 22(3):216-24. PubMed ID: 19453345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uses of drugs not described in the package insert (off-label uses).
    Committee on Drugs. American Academy of Pediatrics
    Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
    Guhl G; Díaz-Ley B; Fernández-Herrera J
    Actas Dermosifiliogr; 2008; 99(1):5-33. PubMed ID: 18206084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in dermatopharmacology--strength and weakness of recently of approved drugs (I).
    Chang YC; Maibach HI
    Int J Clin Pharmacol Ther; 1997 May; 35(5):188-94. PubMed ID: 9174873
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug treatments for skin disease introduced in 2006.
    Skin Therapy Lett; 2007 May; 12(4):4-7. PubMed ID: 17551663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.